Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) EPS (Weighted Average and Diluted) (2023 - 2026)

ArriVent BioPharma has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.96 for Q1 2026.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.96 for Q1 2026, up 49.47% from a year ago — trailing twelve months through Mar 2026 was -$3.47 (up 7.96% YoY), and the annual figure for FY2025 was -$4.32, down 68.75%.
  • EPS (Weighted Average and Diluted) reached -$0.96 in Q1 2026 per AVBP's latest filing, down from -$0.78 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.61 in Q3 2024 and bottomed at -$10.79 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.9 (2025), compared with a mean of -$3.18.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 93.98% in 2024 before it tumbled 171.43% in 2025.
  • Over 4 years, EPS (Weighted Average and Diluted) stood at -$7.69 in 2023, then skyrocketed by 92.07% to -$0.61 in 2024, then fell by 27.87% to -$0.78 in 2025, then fell by 23.08% to -$0.96 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AVBP at -$0.96 in Q1 2026, -$0.78 in Q4 2025, and -$0.83 in Q3 2025.